10x Genomics (TXG) Q4 2025 earnings review
Austerity Works, But The Growth Engine Has Stalled
10x Genomics delivered a masterclass in cost control but failed to reignite top-line momentum. While Q4 Operating Loss narrowed dramatically to $19.5M (from $49.8M a year ago), revenue remained effectively flat (+1% YoY). The underlying story is alarming: Instrument revenue collapsed 36% YoY, a massive red flag for future consumable pull-through. While Consumables (+6%) provided stability, the FY26 guidance ($600-625M) implies continued stagnation. The company is leaner, but it is shrinking in real terms relative to its previous growth trajectory.
🐂 Bull Case
Management has successfully rightsized the ship. Operating expenses fell 18% YoY in Q4, and Net Loss was cut by two-thirds. With $523M in cash, the burn rate is no longer an existential threat.
Spatial consumables grew 14% YoY in Q4, driven by the Xenium platform. The shift toward image-based spatial biology is working, validating the product strategy despite macro headwinds.
🐻 Bear Case
Instruments are the 'razors' that sell the 'blades.' Instrument revenue plummeted 36% in Q4 and 39% for the full year. This inability to place new hardware severely caps the future total addressable market for consumables.
FY26 revenue guidance of $600-625M represents 0-4% growth against adjusted FY25 numbers (and a decline vs reported). After a year of 'macro challenges,' the company sees no meaningful recovery in demand next year.
⚖️ Verdict: 🔴
Bearish. The improvement in cash burn is commendable, but a growth stock with zero growth and collapsing hardware sales is a value trap. Until instrument placements stabilize, the long-term consumable stream is at risk.
Key Themes
Instrument Sales Freefall
The CapEx freeze continues to batter 10x Genomics. Instrument revenue fell 36% YoY to just $15.5M in Q4. This is not a one-off shock; it is a deepening trend (Q1 -42%, Q2 -39%, Q3 -37%). Without placing new boxes, the company cannot expand its recurring revenue base. Management blamed 'cautious customer spending,' but a decline of this magnitude suggests potential saturation or competitive displacement.
Operational Austerity
The most positive metric in the report is the 18% reduction in Operating Expenses ($132.6M vs $160.8M prior year). R&D spend dropped significantly, and SG&A was tightened. This discipline allowed the company to narrow its Operating Loss to $19.5M, a massive improvement from the $49.8M loss in 24Q4. The path to breakeven is now visible, provided revenue doesn't deteriorate further.
Spatial Consumables Resilience
While hardware struggles, the Spatial Biology segment shows life. Spatial Consumables revenue reached $41.0M in Q4, up 14% YoY and 16% sequentially. This confirms that existing Xenium customers are ramping up usage. However, Spatial Instruments revenue dropped 30% YoY, threatening to choke this growth engine in future quarters.
Macro & Funding Headwinds
Management continues to cite 'funding pressures' and 'policy uncertainty' as primary reasons for the lack of growth. While academic funding is notoriously cyclical, the prolonged nature of this downturn (impacting the entirety of FY25) raises concerns about structural changes in research budgets or a shift in prioritization away from single-cell genomics.
AI & Translational Partnerships
The company is attempting to pivot the narrative toward data. New partnerships with the Cancer Research Institute, PharosAI, and Dana-Farber aim to build 'AI-ready datasets.' This is a necessary strategic shift to remain relevant, positioning 10x tools as the data generators for the AI bio-revolution.
Other KPIs
Stable. Cash increased by $130M year-over-year (aided by litigation settlements earlier in the year). The strong balance sheet is a key defender of the stock price, giving them runway to weather the current CapEx winter.
Stable. Improved from 67% in the prior year. Lower inventory write-downs and warranty costs helped, though manufacturing costs rose. Maintaining high margins is critical as volume growth has evaporated.
Stabilizing. Up 3% YoY and 9% sequentially. After several quarters of concern regarding elasticity and pricing pressure from new lower-cost assays (Flex), the core revenue stream appears to have found a floor.
Guidance
Stagnant. This compares to reported FY25 revenue of $642.8M (implying a decline) or adjusted FY25 revenue of $598.7M (implying 0% to 4% growth). This is a deceleration from the historical growth rates investors expect and confirms that 2026 will be another year of transition.
Key Questions
Instrument Strategy
With instrument revenue down nearly 40% for the year, is there a plan to subsidize hardware placement to protect the long-term consumable tail, or is this the new normal for demand?
Single Cell Saturation
Is the Single Cell market saturated? 0-4% growth guidance suggests the company is struggling to find new customers beyond the existing install base.
China Exposure
With tariff concerns mentioned in previous quarters, what is the specific assumption for China revenue embedded in the 2026 guidance?